On the Treatment of a Patient with Ataxic Syndrome by Microdoses of Levo- and Carbo-Dopa. Post COVID Treatment
DOI:
https://doi.org/10.14738/jbemi.95.13206Keywords:
biocorrection, levo- and carbo-dopa, ataxic syndrome, cerebellar neuropathy, long COVID.Abstract
The neurological evaluation and the report of the physioterapist are described for a patient who from 2018 was blocked by neurological status with different problems that concerned his different functions of the nervous systems on coordination and balance, motor exam and even speech, after the treatment with microdoses of Sinemet CR for two months. The satisfation is reported by the neurologist regarding the results on the patient recovery. Post COVID disorders are suggested to be treated with special indication for long COVID.
References
Furukawa Y, Graf WD, Wong H, Shimadzu M, Kish SJ: Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 2001, 56: 260-263.
Furukawa Y, Kish SJ, Fahn S: Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiency. Ann Neurol 2004, 55: 147-148.
Furukawa Y: Update on dopa-responsive dystonia: locus heterogeneity and biochemical features. Adv Neurol 2004, 94: 127-138.
Brunstrom JE, Bastian AJ, Wong M, Mink JW: Motor benefit from levodopa in spastic quadriplegic cerebral palsy. Ann Neurol 2000, 47: 662-665.
Karlov VA, Gleiser MA: Reactivity of the dopa-dopamine-noradrenaline-adrenaline system in epileptic patients. Neurosci Behav Physiol 1986, 16: 49-53. 136
Mann DM, Yates PO, Marcyniuk B: Monoaminergic neurotransmitter systems in presenile Alzheimer's disease and in senile dementia of Alzheimer type. Clin Neuropathol 1984, 3: 199-205.
Mann DM, Yates PO, Marcyniuk B: Dopaminergic neurotransmitter systems in Alzheimer's disease and in Down's syndrome at middle age. J Neurol Neurosurg Psychiatry 1987, 50: 341-344.
Leguire LE, Rogers GL, Bremer DL, Walson P, Hadjiconstantinou-Neff M: Levodopa and childhood amblyopia. J Pediatr Ophthalmol Strabismus 1992, 29: 290-298.
Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML: Longitudinal study of levodopa/carbidopa for childhood amblyopia. J Pediatr Ophthalmol Strabismus 1993, 30: 354-360.
Leguire LE, Rogers GL, Bremer DL, Walson PD, McGregor ML: Levodopa/carbidopa for childhood amblyopia. Invest Ophthalmol Vis Sci 1993, 34: 3090-3095.
Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML: Levodopa/carbidopa treatment for amblyopia in older children. J Pediatr Ophthalmol Strabismus 1995, 32: 143-151.
Leguire LE, Rogers GL, Walson PD, Bremer DL, McGregor ML: Occlusion and levodopa-carbidopa treatment for childhood amblyopia. J AAPOS 1998, 2: 257-264.
Leguire LE, Jende DL, Nairus TM, Walson PD, Rogers GL, Bremer DL et al.: Levodopa-carbidopa and childhood retinal disease. J AAPOS 1998, 2: 79-85.
Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz MH: Attention-deficit hyperactivity disorder: a study of association with both the dopamine transporter gene and the dopamine D4 receptor gene. Am J Med Genet 2001, 105: 471-478.
Roman T, Rohde LA, Hutz MH: Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder. Am J Pharmacogenomics 2004, 4: 83-92.
Roman T, Polanczyk GV, Zeni C, Genro JP, Rohde LA, Hutz MH: Further evidence of the involvement of alpha-2A-adrenergic receptor gene (ADRA2A) in inattentive dimensional scores of attention-deficit/hyperactivity disorder. Mol Psychiatry 2006, 11: 8-10.
Roman T, Rohde LA, Hutz MH: A role for neurotransmission and neurodevelopment in attentiondeficit/hyperactivity disorder. Genome Med 2009, 1: 107.
Gadow KD, Pinsonneault JK, Perlman G, Sadee W: Association of dopamine gene variants, emotion dysregulation and ADHD in autism spectrum disorder. Res Dev Disabil 2014, 35: 1658-1665.
Sivam SP: Dopamine, serotonin and tachykinin in self-injurious behavior. Life Sci 1996, 58: 2367-2375.
Tong J, Fitzmaurice PS, Ang LC, Furukawa Y, Guttman M, Kish SJ: Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 2004, 55: 125-129.
Wong DF, Ricaurte G, Grunder G, Rothman R, Naidu S, Singer H et al.: Dopamine transporter changes in neuropsychiatric disorders. Adv Pharmacol 1998, 42: 219-223.
Perry D, Birthi P, Salles S, McDowell S: Neuroleptic malignant syndrome associated with the use of carbidopa/levodopa for dystonia in persons with cerebral palsy. PM R 2012, 4: 383-384.
Nataf S. An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. J Med Virol 2020; doi: 10.1002/jmv.25826.
https://pubmed.ncbi.nlm.nih.gov/32246784/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267273/
Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020;95(8):e1060-e1070.
Czeisler MÉ , Lane RI, Petrosky E, et al. Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June $–30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69:1049–1057. 137
Forte G, Favieri F, Tambelli R, Casagrande M. COVID-19 Pandemic in the Italian Population: Validation of a Post-Traumatic Stress Disorder Questionnaire and Prevalence of PTSD Symptomatology. Int J Environ Res Public Health. 2020;17(11):4151.
Berthelot N, Lemieux R, Garon-Bissonnette J, et al. Uptrend in distress and psychiatric symptomatology in pregnant women during the coronavirus disease 2019 pandemic. Acta Obstet Gynecol Scand. 2020; 99: 848–855.
Restauri N, Sheridan AD. Burnout and Posttraumatic Stress Disorder in the Coronavirus Disease 2019 (COVID-19) Pandemic: Intersection, Impact, and Interventions. J Am Coll Radiol. 2020;17(7):921-926. 31.https://medium.com/swlh/dopamine-fasting-2-0-the-hot-silicon-valley-trend-7c4dc3ba2213
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 G. Tarro, D. Raiderman
This work is licensed under a Creative Commons Attribution 4.0 International License.
